Personalised Medicines (ATMPs)
Advanced therapy medicinal products (ATMPs) are a relatively new class of medicine incorporating cell and gene therapies and tissue/genetic engineering. They are known for being highly innovative and often very effective, however they also come with a high price and usually low quantities of evidence. The challenge for health technology assessment (HTA) bodies is for processes to be flexible enough to work for both traditional, and these new medicines despite their very different profiles. This page gives some examples of ATMPs in health systems around Europe, and some of the regulatory framework underpinning their use.